Company Description
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors.
The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications.
In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product.
Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jun 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 224 |
| CEO | Dr. Lynn Seely M.D., Ph.D. |
Contact Details
Address: 201 Haskins Way South San Francisco, California 94080 United States | |
| Phone | 650 695-0677 |
| Website | lyell.com |
Stock Details
| Ticker Symbol | LYEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001806952 |
| CUSIP Number | 55083R104 |
| ISIN Number | US55083R1041 |
| Employer ID | 83-3006753 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard D. Klausner M.D. | Founder and Executive Chairman |
| Dr. Lynn Seely M.D., Ph.D. | President, Chief Executive Officer and Director |
| Charles W. Newton | Chief Financial Officer |
| Stephen J. Hill | Chief Operating Officer |
| Dr. Gary Lee Ph.D. | Chief Scientific Officer |
| Elizabeth Homans | Consultant |
| Prof. Stanley R. Riddell M.D. | Founder and Scientific Advisor |
| Dr. Crystal L. Mackall M.D. | Founder and Scientific Advisor |
| Nellie Dillery | Director of Accounting |
| Ellen Rose | Senior Vice President of Communications and Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | ARS | Filing |
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2024 | 10-K | Annual Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |